| Literature DB >> 32958851 |
Yukiko Goshima1,2, Yosuke Okada1, Keiichi Torimoto1, Yoshihisa Fujino3, Yoshiya Tanaka4.
Abstract
Only a few reports have examined vascular endothelial function before and after educational hospitalization and the factors that affect it in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to assess vascular endothelial function before and after educational hospitalization and identify factors that affect it. In 65 patients with T2DM who underwent peripheral arterial tonometry (EndoPAT) before and after hospitalization, vascular endothelial function (reactive hyperemia index [RHI]), glucose metabolism, lipid metabolism, and blood pressure were assessed before and after hospitalization. The primary endpoint was hospitalization-induced changes in vascular endothelial function. Educational hospitalization significantly improved the natural logarithmically scaled RHI (L_RHI) from 0.555 ± 0.212 to 0.625 ± 0.245 (p = 0.012). Multivariable logistic regression analysis identified hypoglycemia during hospitalization as the single factor that significantly altered vascular endothelial function (p = 0.019). The odds of achieving normal vascular endothelial function were 0.08 times lower (95% confidence interval, 0.01-0.67) for each episode of hypoglycemia. Furthermore, multivariable analysis identified hypoglycemia during hospitalization as the single factor that worsened L_RHI. Our study showed that educational hospitalization of patients with T2DM improved vascular endothelial function, and that the development of hypoglycemic episodes had a significant negative impact on normalization of vascular endothelial function.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32958851 PMCID: PMC7506545 DOI: 10.1038/s41598-020-72341-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics (n = 65).
| Mean ± SD | Min | Max | |
|---|---|---|---|
| Age, years | 60.5 ± 12.6 | 22 | 84 |
| Male sex, n (%) | 29 (45) | ||
| BMI (kg/m2) | 26.7 ± 5.0 | 18.2 | 45.7 |
| Duration, years | 8.7 ± 11.1 | 0 | 47 |
| Smoking, n (%) | 28 (43) | ||
| Neuropathy, n (%) | 31 (48) | ||
| Retinopathy, n (%) | 16 (25) | ||
| Nephropathy, n (%) | 21 (32) | ||
| CVD, n (%) | 3 (5) | ||
| Systolic blood pressure, mmHg | 129.7 ± 17.5 | 93 | 171 |
| Diastolic blood pressure, mmHg | 76.5 ± 12.5 | 49 | 112 |
| HbA1c, (%) | 9.5 ± 2.3 | 6.3 | 17.0 |
| Fasting plasma glucose, mg/dL | 158.2 ± 49.6 | 88 | 355 |
| IRI, μU/mL (n = 63) | 7.2 ± 5.9 | 1.3 | 38.9 |
| u-CPR, μg/day (n = 63) | 99.2 ± 65.0 | 0.2 | 355.6 |
Data are mean ± SD, n, or n (%).
SD, standard deviation; BMI, body mass index; HbA1c, hemoglobin A1c; CVD, cardiovascular disease; IRI, immunoreactive insulin; u-CPR, urinary C-peptide immunoreactivity.
Changes in glucose-lowering medications during hospitalization (n = 65).
| Admission | Discharge | |
|---|---|---|
| Day of evaluation after admission | 4.2 ± 2.1 | 18.8 ± 3.0 |
| Diet, n (%) | 15 (23) | 0 (0) |
| Sulfonylurea, n (%) | 37 (57) | 26 (40) |
| Pioglitazone, n (%) | 6 (9) | 11 (17) |
| Metformin, n (%) | 16 (25) | 26 (40) |
| α-Glucosidase inhibitor, n (%) | 3 (5) | 16 (25) |
| Dipeptidyl peptidase-4 inhibitor, n (%) | 28 (43) | 34 (52) |
| Glucagon-like peptide-1 analog, n (%) | 0 (0) | 5 (8) |
| Insulin, n (%) | 2 (3) | 9 (14) |
| Sodium glucose cotransporter 2 inhibitor, n (%) | 1 (2) | 30 (46) |
Data are n (%).
L_RHI, blood glucose, blood pressure, and serum lipid parameters at admission and discharge (n = 65).
| Admission | Discharge | p-value | |
|---|---|---|---|
| L_RHI | 0.555 ± 0.212 | 0.625 ± 0.245 | 0.012 |
| Blood glucose level before breakfast, mg/dL | 149.4 ± 38.3 | 112.4 ± 25.2 | < 0.001 |
| Blood glucose level before lunch, mg/dL | 190.6 ± 74.0 | 125.1 ± 33.3 | < 0.001 |
| Blood glucose level before dinner, mg/dL | 150.9 ± 55.6 | 119.5 ± 31.2 | < 0.001 |
| Blood glucose level after dinner, mg/dL | 218.0 ± 68.0 | 160.1 ± 37.4 | < 0.001 |
| Average glucose, mg/dL | 177 ± 50.4 | 129 ± 21.8 | < 0.001 |
| M-value, mg/dL | 19.0 ± 22.6 | 6.0 ± 4.3 | < 0.001 |
| Systolic blood pressure, mmHg | 130 ± 17.5 | 122 ± 15.6 | < 0.001 |
| Diastolic blood pressure, mmHg | 76 ± 12.5 | 73 ± 10.7 | 0.006 |
| Triglycerides, mg/dL (n = 62) | 155 ± 74.3 | 111 ± 38.7 | < 0.001 |
| LDL-cholesterol, mg/dL (n = 62) | 120 ± 34.9 | 96 ± 27.7 | < 0.001 |
| HDL-cholesterol, mg/dL (n = 62) | 47.9 ± 13.5 | 46.2 ± 10.8 | 0.121 |
| LDL-to-HDL ratio (n = 62) | 2.68 ± 0.95 | 2.19 ± 0.80 | < 0.001 |
Data are mean ± standard deviation, n, or n (%).
L_RHI, natural logarithmically scaled reactive hyperemia index; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Clinical markers associated with L_RHI ≥ 0.51 at discharge.
| Univariable logistic regression | Multivariable logistic regression | |||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Sex, male/female | 0.92 (0.33–2.57) | 0.880 | 0.56 (0.20–4.11) | 0.890 |
| Age, per year | 1.03 (0.99–1.08) | 0.124 | 1.65 (0.75–3.62) | 0.213 |
| BMI, per kg/m2 | 0.93 (0.83–1.03) | 0.158 | 0.91 (0.36–2.27) | 0.841 |
| Duration, years | 1.02 (0.98–1.08) | 0.377 | ||
| ACE-I or ARBs, yes/no | 2.13 (0.72–6.88) | 0.185 | 3.74 (0.65–21.5) | 0.138 |
| Statin, yes/no | 1.30 (0.47–3.75) | 0.614 | ||
| Current smoking, yes/no | 1.07 (0.85–1.37) | 0.577 | 0.91 (0.19–4.36) | 0.909 |
| Average glucose, mg/dL | 1.02 (0.99–1.05) | 0.153 | 0.85 (0.37–1.92) | 0.691 |
| M-value, mg/dL | 1.02 (0.90–1.16) | 0.775 | 1.40 (0.59–3.34) | 0.448 |
| Hypoglycemia, yes/no | 0.19 (0.05–0.64) | 0.010 | 0.08 (0.01–0.67) | 0.019 |
| SBP, mmHg | 1.03 (0.99–1.07) | 0.093 | 0.93 (0.38–2.29) | 0.877 |
| DBP, mmHg | 1.02 (0.98–1.07) | 0.440 | ||
| Triglycerides, mg/dL | 0.99 (0.97–1.00) | 0.076 | ||
| LDL-cholesterol, mg/dL | 1.01 (0.99–1.03) | 0.537 | ||
| HDL-cholesterol, mg/dL | 1.07 (1.01–1.15) | 0.036 | ||
| LDL to HDL ratio | 0.80 (0.46–1.36) | 0.411 | 0.85 (0.41–1.78) | 0.670 |
L_RHI, natural logarithmic scaled reactive hyperemia index; OR, odds ratio; CI, confidence interval; BMI, body mass index; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Figure 1Changes in endothelial function in patients with and without hypoglycemia. #p < 0.05. L_RHI, natural logarithmically scaled reactive hyperemia index.